In-vitro assessment of a PARI LC PLUS® nebuliser utilising a standard inhalation pattern compared to breathing profiles of 3 cyctic fibrosis (CF) patients (Englisch)
- Neue Suche nach: Jauernig, J.
- Neue Suche nach: Jahn, D.
- Neue Suche nach: Stempfle, P.
- Neue Suche nach: Balcke, A.
- Neue Suche nach: Keller, M.
- Neue Suche nach: Aerosol Society
- Neue Suche nach: Jauernig, J.
- Neue Suche nach: Jahn, D.
- Neue Suche nach: Stempfle, P.
- Neue Suche nach: Balcke, A.
- Neue Suche nach: Keller, M.
- Neue Suche nach: Aerosol Society
In:
Drug delivery to the lungs
;
179-182
;
2001
-
ISBN:
- Aufsatz (Konferenz) / Print
-
Titel:In-vitro assessment of a PARI LC PLUS® nebuliser utilising a standard inhalation pattern compared to breathing profiles of 3 cyctic fibrosis (CF) patients
-
Beteiligte:Jauernig, J. ( Autor:in ) / Jahn, D. ( Autor:in ) / Stempfle, P. ( Autor:in ) / Balcke, A. ( Autor:in ) / Keller, M. ( Autor:in ) / Aerosol Society
-
Kongress:Meeting; 12th, Drug delivery to the lungs ; 2001 ; London
-
Erschienen in:Drug delivery to the lungs ; 179-182
-
Verlag:
- Neue Suche nach: Aerosol Society
-
Erscheinungsort:Bristol
-
Erscheinungsdatum:01.01.2001
-
Format / Umfang:4 pages
-
ISBN:
-
Medientyp:Aufsatz (Konferenz)
-
Format:Print
-
Sprache:Englisch
-
Schlagwörter:
-
Datenquelle:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Inhaltsverzeichnis Konferenzband
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 7
-
Advances in treating systemic diseases with aerosolised medicineLaube, B. / Aerosol Society et al. | 2001
- 15
-
A comparison of the immune response exhibited following single dose administration of non-porous and porous poly(DL)lactide-co-glycolide microspheresCocks, E. / Alpar, H. O. / McKenzie, L. / Purewal, T. S. / Aerosol Society et al. | 2001
- 19
-
Microparticle transfer to systemic compartments and subsequent immunopotentiation following pulmonary deliveryEyles, J. E. / Bramwell, V. W. / Williamson, E. D. / Alpar, H. O. / Aerosol Society et al. | 2001
- 23
-
Patient individualized inhalation optimises peripheral lung depositionMullinger, B. / Meyer, T. / Sommerer, K. / Weber, N. / Beckmann, H. / Bernhardt, T. / Scheuch, G. / Aerosol Society et al. | 2001
- 27
-
Respiratory aerosol probe - A tool for inhalation therapy control of longitudinal studiesHaussermann, S. / Brand, P. / Meyer, T. / Scheuch, G. / Aerosol Society et al. | 2001
- 31
-
The in vitro assessment of aerosolised drug deposition using novel oropharyngeal modelsMasoud, O. / Martin, G. P. / Marriott, C. / Nichols, S. / Aerosol Society et al. | 2001
- 35
-
Comparison of the development of a pharmaceutical aerosol in USP and "Biological" throats using computational fluid dynamicsHarrington, L. / Versteeg, H. K. / Ehtezazi, T. / Horsfield, M. A. / Barry, P. W. / O Callaghan, C. / Aerosol Society et al. | 2001
- 39
-
Particle size measurement in aerosol formulationWashington, C. / Aerosol Society et al. | 2001
- 46
-
Characterization of sustained release inhaled Rifampin compared between two different coating methods: Pulsed laser deposition (PLD) and spray dryingCoowanitwong, I. / Kim, W.-S. / Craciun, V. / Kulvanich, P. / Singh, R. / Hughes, J. / Hochhaus, G. / Aerosol Society et al. | 2001
- 50
-
PulmoSphere® particle engineering - Technology development to pilot scale and commercial viabilityVenthoye, G. / Weers, J. / Tarara, T. / Aerosol Society et al. | 2001
- 54
-
Particle size measurement techniques for pharmaceutical device developmentZiegler, J. / Wachtel, H. / Aerosol Society et al. | 2001
- 58
-
Simultaneous analysis of respirable aerosols via laser diffraction and cascade impactionHolmes, C. / Kippax, P. / Newell, H. / Southall, J. / Ward, D. J. / Aerosol Society et al. | 2001
- 62
-
The use of laser diffraction for the assessment of the rate of drug particle detachment from carrier crystals in adhesive mixtures during inhalationde Boer, A. H. / Gjaltema, D. / Hagedoorn, P. / Witt, W. / de Goede, J. / Frijlink, H. W. / Aerosol Society et al. | 2001
- 66
-
Nozzle examination methods for the next generation pharmaceutical impactorRoberts, D. L. / Romay, F. J. / Marple, V. A. / Aerosol Society et al. | 2001
- 70
-
Advanced pulmonary systems: A novel high-performance formulation-integrated dry powder inhaler (FIDPI) for peptide and protein systemic drug deliveryStaniforth, J. N. / Braithwaite, P. / Ganderton, D. / Morton, D. A. V. / Wyber, J.-A. / Parry-Billings, M. / Patel, N. / Price, R. / Tservistas, M. / Aerosol Society et al. | 2001
- 74
-
Skye Dry™ for stabilization of metered dose inhaler suspension formulationsMueller-Walz, R. / Gilchrist, P. / Herzog, K. / Niederlaender, C. / Pignatelli, G. / Aerosol Society et al. | 2001
- 78
-
Aerosol generation using a dispersion mechanism based on powder flow characteristicsCrowder, T. M. / Hickey, A. J. / Aerosol Society et al. | 2001
- 79
-
Evaluation of pressurised metered dose inhalers (pMDIs) for pulmonary delivery of proteins and peptidesKoppenhagen, F. / Pritchard, Y. / Fulton, C. / Beynon, G. / Tilley, K. / McKenzie, L. / Oliver, M. J. / Aerosol Society et al. | 2001
- 83
-
Therapeutic Particle EngineeringEdwards, D. A. / Aerosol Society et al. | 2001
- 84
-
Surface characterisation of inhalation microparticles: Physical and chemical analysisEbbens, S. / Luk, S. Y. / Davies, M. C. / Roberts, C. J. / Patel, N. / Aerosol Society et al. | 2001
- 88
-
Recommendations to the FDA regarding the CMC draft guidances for MDIs and DPIs: The work of the ITFG/IPAC-RS tests and methods teamEvans, C. / Aerosol Society et al. | 2001
- 92
-
Test methods for inhalers to check performance under normal use and unintentional misusePurewal, T. / Aerosol Society et al. | 2001
- 99
-
Novel liquid formulation technologies as a tool to design the aerosol performance of nebulisers using an air jet (LC Plus®) or a vibrating membrane principle (E-Flow™)Keller, M. / Lintz, F.-C. / Walther, E. / Aerosol Society et al. | 2001
- 103
-
TouchSpray™ technology: Preliminary results from the in vitro evaluation of Insulin and AlbuminSmart, J. / Stang, R. / Halsall, I. / Chrystyn, H. / Aerosol Society et al. | 2001
- 107
-
The PARI e-Flow™: Tools in the development process of a new inhaler for topic and systemic pulmonary drug deliveryStangl, R. / Aerosol Society et al. | 2001
- 111
-
The consistent delivery valve: An improved valve for metered dose inhalersMahon, G. / Wilby, M. / Helm, S. / Balcombe, K. / Baron, C. / Fradley, G. / Aerosol Society et al. | 2001
- 115
-
Development of an in vitro dissolution-absorption model to evaluate the delivery of aerosolised drug from dry powder inhaler formulationsTee, S. K. / Forbes, B. / Larhrib, H. / Marriott, C. / Martin, G. P. / Aerosol Society et al. | 2001
- 119
-
PowderHale™: A novel high-performance dry powder inhaler formulation technology for targeted and systemic drug deliveryBegat, P. / Green, M. / Morton, D. A. V. / Whittock, A. / Staniforth, J. N. / Aerosol Society et al. | 2001
- 123
-
Particle design for dry powder inhalation systems: The influence of delivery device designParveen, Z. / Ghafoor, I. / Palakodaty, S. / Gilbert, D. J. / Walker, S. E. / Feeley, J. C. / Aerosol Society et al. | 2001
- 127
-
Potential of granulated lactose as a carrier in dry powder inhalationEllison, M. / Lambregts, D. / Dickhoff, B. H. J. / de Boer, A. H. / Frijlink, H. W. / Aerosol Society et al. | 2001
- 131
-
Poly (lactic-co-glycolic acid) microspheres as a means of drug delivery to the lung: The effect of process variables on particle sizeAl-Najar, M. A. / Martin, G. P. / Marriott, C. / Aerosol Society et al. | 2001
- 135
-
The modification of dry powder formulation performance by use of a novel nano-phase force control agentGanderton, D. / Morton, D. A. V. / Simpson, D. / Staniforth, J. N. / Aerosol Society et al. | 2001
- 139
-
Effect of inhalation flow rate on the dosing characteristics of a novel multi dose dry powder inhaler (DPI)Buttrum, M. E. / Dey, F. / Aerosol Society et al. | 2001
- 143
-
Measurement and setting of flow rates in pharmaceutical aerosol dispersion testingCox, R. / Versteeg, H. / Shott, M. J. / Aerosol Society et al. | 2001
- 147
-
Developing methods to demonstrate the pharmaceutical performance of inhaled therapeutic proteinsTilley, K. / Aerosol Society et al. | 2001
- 148
-
The influence of actuator charge on the particle size distribution and plume characteristics of a pMDI productButler, M. / Derbyshire, H. M. / Boyd, G. / Suggett, J. / Aerosol Society et al. | 2001
- 152
-
Guidance on materials compatibility for the manufacture of pharmaceutical aerosols using HFAs (HFA-MDIs)Pittroff, M. / Pischtiak, A. / Aerosol Society et al. | 2001
- 154
-
A new valved holding chamber (VHC) with positive expiratory pressureMitchell, J. P. / Nagel, M. W. / Doyle, C. C. / Bates, S. L. / Wiersema, K. J. / Engelbreth, D. K. / Aerosol Society et al. | 2001
- 157
-
Comparison of valved holding chamber (VHC) performance with HFA-and CFC-formulated Ventolin®Mitchell, J. P. / Nagel, M. W. / Doyle, C. C. / Bates, S. L. / Wiersema, K. J. / Schmidt, J. N. / Aerosol Society et al. | 2001
- 161
-
A novel approach to produce versatile pMDI container closureBradley, L. / Aerosol Society et al. | 2001
- 162
-
Influence of HFA formulations on Spraymister™ valvesVelasco, V. / Aerosol Society et al. | 2001
- 163
-
In vitro evaluation of holding chambers for delivery of inhaled medications to the mechanically ventilated patientMitchell, J. P. / Nagel, M. W. / Doyle, C. C. / Bates, S. L. / Aerosol Society et al. | 2001
- 167
-
Deposition of therapeutic aerosols in the lung periphery by controlled inhalationHaussermann, S. / Brand, P. / Meyer, T. / Scheuch, G. / Aerosol Society et al. | 2001
- 171
-
Evaluation of an optimal device for peripheral deposition in patients with lung emphysemaSommerer, K. / Meyer, T. / Brand, P. / Mullinger, B. / Pohner, A. / Weber, N. / Beckmann, H. / Maas-Enriquez, M. / Scheuch, G. / Aerosol Society et al. | 2001
- 175
-
Adenovirus-mediated gene transfer to respiraory epithelial cells: No inhibition by mucus hypersecretionForbes, B. / Hashmi, N. / Lansley, A. B. / Martin, G. P. / Aerosol Society et al. | 2001
- 179
-
In-vitro assessment of a PARI LC PLUS® nebuliser utilising a standard inhalation pattern compared to breathing profiles of 3 cyctic fibrosis (CF) patientsJauernig, J. / Jahn, D. / Stempfle, P. / Balcke, A. / Keller, M. / Aerosol Society et al. | 2001
- 183
-
Effect of operating pressure, drug concentration and volume fill on the nebulisation efficiency of jet nebulisersBalcke, A. / Jahn, D. / Stempfle, P. / Schuschnig, U. / Keller, M. / Aerosol Society et al. | 2001
- 187
-
Smoothing the stepped structure of the upper airway reconstructed from the rapid MR scansEhtezazi, T. / Horsfield, M. A. / Barry, P. W. / O Callaghan, C. / Aerosol Society et al. | 2001
- 191
-
A potential mucosal adjuvant for nasal delivery of vaccines: Zinc-Chitosan particlesMcHugh, C. J. / Somavarapu, S. / Singh, J. / Bramwell, V. / Alpar, H. O. / Aerosol Society et al. | 2001